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Abstract
Background: Thymidylate synthase (TS) is known to have a unique 28 bp tandemly repeated
sequence in the promoter region, and the majorities of subjects have a heterozygous double
repeat/triple repeat genotype in their non-cancerous tissue. Loss of heterozygosity (LOH) at the
TS locus is known to occur in cancer patients, but there is no evidence that it is present in
precancerous tissue. The aim of this study was to analyze the frequency and timing of LOH at the
TS locus in Barrett-associated adenocarcinoma (BA) and its precursory lesions, such as intestinal
metaplasia (IM) and dysplasia.
Methods: One hundred twenty-three samples (including 37 with gastroesophageal reflux disease
(GERD), 29 with IM, 13 with dysplasia, and 44 with BA) were obtained from 100 patients. Biopsies
were obtained from the lower esophageal mucosa/IM/dysplasia/BA, when available. Normal
squamous tissue from the upper esophagus was taken as a control. All tissues were analyzed for
the TS genotype and TS mRNA expression using the real-time reverse-transcription polymerase
chain reaction (RT-PCR) method after laser-capture microdissection.
Results: Among the patients with informative heterozygous genotype in their control samples, no
sample with LOH at the TS locus was observed in the lower esophageal mucosa in GERD patients
(0/22 samples). However, 6 out of 21 samples (28.6%) had LOH in IM, 2 of 7 (28.6%) in dysplasia,
and 10 of 25 (40.0%) in BA. No significant difference in TS mRNA expression levels was observed
between TS genotypes.
Conclusion: Our results demonstrate that LOH is a relatively frequent and early event in the IM-
BA sequence.
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Thymidylate synthase (TS), which is located on 18p11.32,
is the only de novo source of the thymine base, and its reac-
tion is one of the rate-limiting steps in DNA synthesis [1].
5-fluorouracil (5-FU) inhibits TS by forming a stable ter-
nary complex among 5,10-methylenetetrahydrofolate, TS,
and fluoro-dUMP, the metabolite of 5-FU. Based on this
mechanism, the TS expression level is regarded as a pre-
dictor of response to 5-FU-based chemotherapy, and
patients with low TS reported having better prognoses
than those with high TS [2,3]. The TS gene is known to
have a unique 28-bp tandemly repeated sequence in the
5'-untranslated region (5'-UTR), and is polymorphic in
the number of these repetitions [4]. Most individuals have
a homozygous double-tandem repeat (2R/2R), a
homozygous triple repeat (3R/3R), or a heterozygous (2R/
3R) genotype. It has been reported that the 3R/3R geno-
type is associated with higher levels of TS mRNA and/or
protein expression than the 2R/2R genotype, suggesting
that this 5'-UTR polymorphism can regulate TS transcrip-
tion or translation [5-8]. In addition, a G/C single nucle-
otide polymorphism (SNP) has been identified within the
3R allele, and segregates the 3R allele into 3RG and 3RC
[9,10]. The 3RC allele can abolish the increased transcrip-
tional activity of the 3R variant in vitro by altering a tran-
scription factor-binding site [10]. Recently, another
polymorphism, a 6 bp insertion/deletion at bp 1494 in
the 3'-untranslated region (3'-UTR) of TS gene, was iden-
tified [11] and is thought to influence the intratumoral TS
mRNA level in vivo [12].
Using this 5'-UTR polymorphism as a heterozygous
marker, we have reported that there is a high incidence of
loss of heterozygosity (LOH) at the TS locus in colorectal
cancer tissue, and have demonstrated that the TS genotype
in cancer tissue modulated by LOH to give either a 2R/loss
or 3R/loss situation influences the chemosensitivity to 5-
FU-related drugs and the prognosis of colorectal cancer
patients [13]. However, when and how this LOH occurs in
cancer cells has never been properly evaluated. If it occurs
at an early stage of carcinogenesis, it may be used not only
as a predictive marker of chemotherapy response but also
as a good biomarker for early cancer detection or for iden-
tifying high-cancer-risk patients. Barrett's-associated aden-
ocarcinoma exhibits a good sequence in which to examine
this question because the stepwise development of this
carcinoma has been well defined.
Barrett's esophagus, which is defined as the replacement
of the normal squamous epithelium of the lower esopha-
gus by metaplastic columnar epithelium, occurs in
patients with chronic gastroesophageal reflux [14]. The
cancer risk of patients with this condition is estimated to
be 125 times as high as that of the general population
[15], and it predisposes a patient to dysplasia and eventu-
ally adenocarcinoma [16]. Surveillance of Barrett's
esophagus patients is conducted by frequent and regular
endoscopic examinations, but several studies have shown
that Barrett's esophagus does not progress to cancer in
most patients [17-19]. Thus, most patients will not benefit
from endoscopic surveillance because their lesions will
not become cancerous during their lifetimes [20]. These
observations indicate the need for objective and precise
biomarkers of neoplastic progression in Barrett's esopha-
gus.
In this study, frequencies of LOH at TS loci were evaluated
in each step of carcinogenesis, such as reflux esophagitis,
intestinal metaplasia (IM), dysplasia, and Barrett's-associ-
ated adenocarcinoma (BA). The aim of this study is to
determine the frequency and timing of LOH at the TS
locus. In addition, intratumoral TS mRNA expression lev-
els were measured in BA patients in order to determine
whether these TS polymorphisms were associated with TS
levels.
Methods
Patients and Samples
One hundred patients (73 males and 27 females) with
gastroesophageal reflux disease (GERD), intestinal meta-
plasia (IM), dysplasia or Barrett's-associated adenocarci-
noma (BA) were included in this study. Written informed
consent was obtained from each patient according to
institutional regulations.
Biopsies were performed by endoscopy or surgically from
lower esophagus (squamous epithelium 3 cm above the
gastroesophageal junction) (37 samples), IM (29 sam-
ples), dysplasia (13 samples), and BA (44 samples) where
available. Since 18 patients had two or more different
pathological tissue types (e.g.: IM and BA) in their lesions,
multiple biopsies were taken from these 18 patients, one
sample being taken from each tissue type (Table 1).
In each patient, normal squamous epithelium 20 cm
below the incisors was taken by endoscopy as a control
sample. This study has been approved by the ethics com-
mittee in the University of Southern California, and has
been performed in accordance with the Declaration of
Helsinki.
In 32 out of 44 BA patients, the data of TS genotype and
LOH status were already reported previously [21].
Microdissection
The frozen samples were embedded in optimal cutting
temperature (O.C.T.) compound (Sakura Finetek U.S.A.,
Inc., Torrance, CA) and cut into serial sections with a
thickness of 20 μm. Sections were mounted on uncoated
glass slides and stored at -80°C. For histological diagno-Page 2 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:157 http://www.biomedcentral.com/1471-2407/9/157sis, one slide was stained with H&E and evaluated by a
pathologist. Before microdissection, sections were air-
dried, fixed in 70% ethanol for 3 minutes and washed in
H2O for 2 min. Afterwards, they were stained with nuclear
fast red (NFR, American MasterTech Scientific, Inc., Lodi,
CA) for 20 seconds and again washed in H2O for 30 sec-
onds. Samples were then dehydrated in a stepwise man-
ner with 70% ethanol, 95% ethanol and 100% ethanol
for 30 seconds each, followed by incubation in xylene for
5 minutes and complete air-drying. Normal squamous
cell control samples were dissected from the slides using a
scalpel. All other sections were selectively dissected by
laser captured microdissection (P.A.L.M. microsystem,
Leica, Wetzlar, Germany) according to the standard proce-
dure [22]
RNA Isolation and cDNA Synthesis
RNA isolation from OCT-embedded specimens was done
according to a proprietary procedure of Response Genet-
ics, Inc. (US patent number 6,248,535) [23]. In brief, tis-
sue samples were placed in 4 M dithiothreitol (DTT)-
GITC/sarc (4 M guanidinium isothiocyanate, 50 mM Tris-
HCl, pH 7.5, 25 mM EDTA) (Invitrogen: cat. no. 15577-
018). To the tissue suspensions were added 50 μL of 2 M
sodium acetate, pH 4.0, followed by 600 μL of freshly pre-
pared phenol/chloroform/isoamyl alcohol (250:50:1).
The suspensions were centrifuged at 13,000 rpm for 8 min
in a chilled (8°C) centrifuge. The upper aqueous phase
was removed and combined with glycogen (10 μL) and
300–400 μL of isopropanol. The tubes were left standing
at -20°C for 30–45 min to precipitate the RNA. After cen-
trifugation at 13,000 rpm for 7 min in a chilled (8°C) cen-
trifuge, the supernatant was carefully poured off and the
pellet was re-suspended in 50 μL of 5 mM Tris. Afterwards,
cDNA was prepared as previously described [24]. In brief,
20 μL 5× Moloney murine leukemia virus (MMLV) buffer
(containing 250 mmol/L Tris-HCl [pH 8.3], 375 mmol/L
KCl, and 15 mmol/L MgCl2; Life Technologies, Gaithers-
burg, Md.), 10 μL dithiothreitol (100 mmol/L; Life Tech-
nologies), 10 μL dNTP (each type 10 mmol/L; Amersham
Pharmacia Biotech), 0.5 μL random hexamers (50 OD
dissolved in 550 μL of 10 mmol/L Tris-HCl [pH 7.5], and
1 mmol/L EDTA; Amersham Pharmacia Biotech), 2.5 μL
bovine serum albumin (3 mg/ml in 10 mmol/L Tris-HCl
[pH 7.5], Amersham Pharmacia Biotech), 2.5 μL RNAse
inhibitor (5× 1000 units; Amersham Pharmacia Biotech),
and 5 μL MMLV reverse transcriptase (200 U/μL; Life
Technologies), added to a total volume of 50.5 μL. Reac-
tion temperatures were first at 26°C for 8 min, then at
42°C for 45 min,, finally at 95°C for 5 min.
Real-time reverse transcriptase polymerase chain reaction 
(RT-PCR) quantification of mRNA expression
Quantitation of TS mRNA and an internal reference gene
(β-actin) was done using a fluorescence-based real-time
detection method (ABI PRISM 7900 Sequence Detection
System (TaqMan®) Perkin-Elmer (PE) Applied Biosystem,
Foster City, CA, USA), as described previously [24-26].
The PCR reaction mixture consisted of each primer (1200
nM), 200 nM probe, 0.4 U of AmpliTaq Gold Polymerase,
200 nM concentrations of each of dATP, dCTP, dGTP and
dTTP, 3.5 mM MgCl2 and 1× Taqman Buffer A containing
a reference dye, to a final volume of 20 μl (all reagents
from PE Applied Biosystems, Foster City, CA, USA).
Cycling conditions were 50°C for 2 min, 95°C for 10
min, followed by 46 cycles at 95°C for 15 s and 60°C for
1 min. The sequence of primers and probes of TS and β-
actin was described previously [13].
Gene expression values (relative mRNA levels) are
expressed as ratios (differences between the Ct values)
between the genes of interest (TS in this case) and an inter-
nal reference gene (β-actin) that provides a normalization
factor for the amount of RNA isolated from a specimen.
DNA Extraction, genotyping
Genomic DNA was extracted using the QIAamp kit (Qia-
gen, Valencia, CA). The promoter region (5'-UTR) of the
TS gene was amplified by the polymerase chain reaction
using the primers described previously [13]. The PCR
primers are designed to flank the region of the tandem
repeats. PCR was performed using the conditions
described previously [7]. The PCR products were analyzed
by electrophoresis on a 10% TBE-urea polyacrylamide gel
Table 1: Patient characteristics
The number of patients 100
Male 73
Female 27
Age (median) 65
Pathological type (in descending order of)
Reflux esophagitis 30
Intestinal metaplasia 22 ()
Dysplasia 4
Barrett's adenocarcinoma 44 ()
Race
Caucasian 89
Asian 6
Hispanic 3
African-American 1
Native American 1
TS genotype in normal tissue
2R/2R 24
2R/3R 57
3R/3R 19
 Including 4 patients from each of whom 2 samples of different 
diseased tissues were taken (e.g: reflux esophagitis and intestinal 
metaplasia).
 Including 9 patients from each of whom 2 samples of different 
diseased tissues were taken, and 5 patients from each of whom 3 
were taken.Page 3 of 9
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ments with an estimated length of 107 and 135 bp, which
represent the two- and three-repeat (2R and 3R)
sequences, respectively. The TS genotypes were classified
into 2R-homozygote (2R/2R), 3R-homozygote (3R/3R),
and 2R/3R heterozygote in normal tissue. LOH in 2R/3R
heterozygous individuals was detected by comparing the
genotype of the normal control sample obtained in the
upper and lower esophagus where GERD, IM, dysplasia,
or BA were present in the same patient. LOH was indi-
cated by loss of either the 2R (3R/loss) or the 3R band
(2R/loss) (Fig 1A). A G/C polymorphism in triple repeat
sequence was analyzed as described previously [9].
3'-UTR polymorphism was determined using PCR. The
primers were as follows: forward primer 5'-GCTGAG-
TAACACCATCGATCATG-3' and reverse primer 5'-GCGT-
GGACGAATGCAGAAC-3'. Cycling conditions were 50°C
for 2 min, 95°C for 10 min, followed by 46 cycles at 95°C
for 15 s and 64°C for 1 min. PCR products which con-
tained the 6 bp polymorphic region were loaded in an
Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA), and the
6 bp difference was detected (Fig. 1B).
Statistical analysis
TS mRNA expression levels in esophageal adenocarci-
noma were compared between the TS genotype groups by
using the Mann-Whitney U test for comparing two
groups, and the Kruskal-Wallis test for 3 groups. All
reported P values are two-sided and statistical significance
was set at a P-value of less than 0.05.
Results
Frequency of LOH at TS 5'-UTR locus in IM-BA sequence
The patients with informative heterozygous genotype in
the 5'-UTR polymorphism in their normal squamous tis-
sues were evaluated the presence of LOH in their IM, dys-
plasia, and BA tissues. The frequencies of LOH in each
pathologic group, which were calculated on the basis of
the number of samples examined are shown in Table 2.
A (left side): Detection of TS 5'-UTR polymorphismFigure 1
A (left side): Detection of TS 5'-UTR polymorphism. Thymidylate synthase (TS) 5'-UTR genotype analysis in matched 
normal (N) and tumor (T) DNA. The upper and lower bands represent PCR products from amplification of the TS segment 
containing 3R and 2R, respectively. Each patient has a heterozygous 2R/3R genotype in normal tissue, as indicated by the pres-
ence of both bands. Case 1: Loss of heterozygosity (LOH) gives rise to a tumor with a 2R/loss genotype. Case 2: LOH does 
not occur. Case 3: LOH gives rise to a tumor with a 3R/loss genotype. 1B (right side): Detection of TS 3'-UTR polymor-
phism. Thymidylate synthase (TS) 3'-UTR genotype analysis in matched normal(N) and tumor (T) DNA. The middle lane 
shows the double bands in 109 bp and 103 bp, representing the heterozygous 6 bp insertion/deletion. The right lane shows the 
single band in 109 bp, representing the loss of the 103 bp band.Page 4 of 9
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the TS locus were observed in the lower esophageal
mucosa (0/22 samples)), 6 out of 21 samples (28.6%)
had LOH in IM, 2 out of 7 (28.6%) in dysplasia, and 10
out of 25 (40.0%) in BA.
The frequency of LOH at the 3'-UTR locus was also evalu-
ated in cancer patients. In 14 informative heterozygous
patients, the frequency of LOH was 35.7%, which was
close to the frequency of LOH at the 5'-UTR locus. There
were 3 patients who had LOH at the 5'-UTR locus and also
had a heterozygous genotype at the 3'-UTR locus, and all
3 patients additionally showed LOH at the 3'-UTR locus.
TS 5'-UTR genotype in different histological tissues from 
the same patient
Eleven BA patients had IM and/or dysplasia adjacent to
BA, and 9 out of 11 patients showed the heterozygous 2R/
3R genotype in their 5'-UTR loci (Table 3). Of these 9
patients, 4 had LOH in their BA tissues. Of these 4, 2 also
showed LOH in their precursor tissues, such as IM or dys-
plasia, whereas the other 2 patients showed LOH only in
their BA tissues, not in the precursor tissues. This data sug-
gests that LOH sometimes occurs in the early stages of car-
cinogenesis, and that the timing of the appearance of LOH
is not always the same in every patient.
Table 2: Frequency of 5'-UTR loss of heterozygosity (LOH) in low esophagus, IM, dysplasia and BA tissues
Low esophagus (LE) (n = 37)
Genotype in normal tissues 2R/2R 2R/3R 3R/3R
Number of samples 8 22 7
Genotype in LE tissues 2R/loss 2R/3R 3R/loss
Number of samples 0 22 0
Frequency 0% 100% 0%
Intestinal metaplasia (IM) (n = 29)
Genotype in normal tissues 2R/2R 2R/3R 3R/3R
Number of samples 3 21 5
Genotype in IM tissues 2R/loss 2R/3R 3R/loss
Number of samples 5 15 1
Frequency 23.80% 71.40% 4.80%
Dysplasia (n = 13)
Genotype in normal tissues 2R/2R 2R/3R 3R/3R
Number of samples 4 7 2
Genotype in dysplasia tissues 2R/loss 2R/3R 3R/loss
Number of samples 1 5 1
Frequency 14.30% 71.40% 14.30%
Barrett associated adenocarcinoma (BA) (n = 44)
Genotype in normal tissues 2R/2R 2R/3R 3R/3R
Number of samples 15 25 4
Genotype in BA tissues 2R/loss 2R/3R 3R/loss
Number of samples 3 15 7
Frequency 12% 60% 28%Page 5 of 9
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genotypes
The comparison of TS mRNA expression levels in BA tis-
sue in 5'-UTR genotypes are shown in Figs. 2A, B. When
patients were classified as 2R group patients (2R/2R, 2R/
loss), 3R group (3R/3R, loss/3R), and 2R/3R group,
according to the number of repeats, no difference of
median TS mRNA levels was observed between the groups
(p = 0.69). When patients were classified in the 3RG
group, the genotype that contained the 3RG allele, (2R/
3RG, 3RC/3RG, 3RG/3RG) and the non-3RG group (2R/
2R, 2R/3R, 3RC/3RC) according to the number of repeats
and the G/C SNP, there was also no significant difference
in median TS mRNA levels between these 2 groups (p =
0.66). There was also no difference in median TS mRNA
levels between the patients with LOH and those without
LOH in 5'UTR genotypes in 31 informative BA patients (p
= 0.53).
The same result was observed in 3'-UTR polymorphism,
so that no significant difference was seen between ins/ins,
ins/del, and del/del groups (p = 0.68) (Fig. 3).
Discussion
LOH in tumor suppressor gene loci, such as 17p (p53),
18q (DCC), 9p (CDKN2/p16), 5q (APC), and 10q (PTEN),
has been reported to be a common genetic alteration in
the metaplasia-dysplasia-carcinoma sequence in Barrett's
esophagus [20,27-33]. Several previous studies demon-
strated that LOH in Barrett's esophagus was observed in
the early stage of this sequence [20,28,29]. Suspiro et al.
reported that LOH on 9p and 17p were detected in 35%
and 39% of Barrett's esophagus patients without any evi-
dence of adenocarcinoma, and concluded that the pres-
ence of these LOH may be useful markers for risk
stratification within endoscopic surveillance [27].
In this study, we observed 28.6% of LOH at the TS 5'-UTR
locus even in IM tissue, which indicates that this genetic
alteration may occur at some early stage of carcinogenesis.
However, no LOH was observed in the lower esophageal
tissues of GERD patients, suggesting that merely inflam-
mation in the squamous epithelium is not a change suffi-
cient to cause this genetic alteration, but that the
Table 3: TS genotype of Barrett's-associated adenocarcinoma 
patients who had adjacent intestinal metaplasia and/or dysplasia
Pt. No. Normal Metaplasia Dysplasia Adenocarcinoma
1 2R/3R 2R/3R N/A 2R/3R
2 2R/3R 2R/loss 2R/loss 2R/loss
3 2R/2R 2R/2R 2R/2R 2R/2R
4 2R/3R 2R/3R 2R/3R 2R/3R
5 2R/3R 2R/3R N/A 2R/3R
6 2R/3R 2R/3R 2R/3R 2R/3R
7 2R/3R 2R/3R N/A 2R/loss
8 2R/3R N/A 2R/3R 2R/3R
9 2R/2R N/A 2R 2R/2R
10 2R/3R N/A 2R/3R loss/3R
11 2R/3R N/A loss/3R loss/3R
Comparison of intratumoral TS mRNA levels with the 5'-UTR genotypeFigure 2
Comparison of intratumoral TS mRNA levels with the 5'-UTR genotype. A: Grouped by the number of repeats. No 
difference was observed between 2R/2R, 2R/3R, and 3R/3R groups. B: Grouped by the number of repeats and G/C SNPs. The 
patients with 2R/3RG, 3RC/3RG, and 3RG/3RG genotypes were classified as the 3RG group, while those with 2R/2R, 2R/3RC, 
and 3RC/3RC were classified as the non-3RG group. There was no difference in TS mRNA levels between these two groups. 
Boxes indicate the first and third quartiles (median inside); bars represent the range of values falling within 1.5-fold the inter-
quartile range.Page 6 of 9
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columnar cells is necessary. Our data showed that, of 4
patients who had LOH in cancer tissue and whose precur-
sor tissues were assessable, 2 had LOH in both cancer and
precursor tissues, while 2 had LOH in cancer tissue only,
but not in the precursor tissues. These data indicate that
the timing of this genetic alteration may vary between
individuals.
In our 11 BA patients who had IM and/or dysplasia adja-
cent to cancer, the allelic loss pattern showed that the
same allele copy was deleted in each individual patient
between cancerous tissue and its precursor tissues. This
observation suggests that BA has a monoclonal tumor cell
population through its carcinogenesis step from IM to BA,
and further confirms that IM and dysplasia are clonal pre-
cursors of BA. Zhuang et al. evaluated genetic clonality by
using a polymorphic marker flanking the APC gene locus
in 12 patients of BA as well as their IM and dysplasia, and
found that identical alterations were observed in BA, dys-
plasia and some IM tissue [34]. Similar results have also
been reported in the previous literature [35,36].
The reason why LOH occurs at the TS locus is still unclear.
TS itself is probably not a target gene of LOH because it is
an essential gene for DNA synthesis. If some unknown
tumor suppressor genes are located close to the TS locus,
the TS gene may be contained in the deleted DNA seg-
ment. Tran et al. examined the prevalence of LOH at
18p11 using six PCR-based polymorphic markers in non-
small cell lung cancer, breast cancer, and glioblastoma,
and found two frequency peaks at 18p11, suggesting that
two potential tumor suppressor genes are present in chro-
mosome 18p [37]. One of these regions is estimated to be
located in between the two markers DS18S59 and
D18S476, where the whole TS gene is located. The result
of this study may support our hypothesis that unknown
tumor suppressor genes are located close to the TS locus.
In our data, no relationship was observed between TS pol-
ymorphisms, either 5'-UTR or 3'-UTR, and TS mRNA
expression. Whether TS polymorphisms in 5'-UTR or 3'-
UTR are associated with TS mRNA expression levels has
been a controversial topic for some years. Mandola et al.
Reported, on the basis of in vitro data that this 5'-UTR pol-
ymorphism is related to the transcriptional activity of the
TS gene [10]. In an vivo study, Morganti et al. found an
association between TS mRNA expression and 5'-UTR pol-
ymorphism [38]. In contrast, Kawakami et al. quantified
the TS mRNA level and the TS protein level, and found no
relation between the genotype and the mRNA level,
although the protein level was significantly related [7].
With respect to the 3'-UTR genotype, Mandola et al.
reported that 6 bp deletion constructs had significantly
decreased mRNA stability compared with 6 bp insertion
constructs in vitro, and that the patients with an ins/ins
genotype had significantly higher TS mRNA levels com-
pared with those with del/del genotype in vivo [12]. In
contrast, another investigation rshowed no association
between 3'-UTR polymorphisms and TS mRNA levels
[39]. Our previous data have shown neither 5'-UTR poly-
morphism nor 3'-UTR polymorphism to be associated
with TS mRNA expression levels in esophageal adenocar-
cinoma [21], a finding that is supported by the present
study.
Conclusion
LOH at the TS locus may occur as an early event in the IM-
BA sequence. Our next question is whether patients with
LOH at the TS locus in their precursor tissue have a higher
cancer risk than those who do not have LOH. For Barrett's
esophagus patients, a prospective study with long-term
surveillance is clearly needed.
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